A Reflection of the New Wave of Immunotherapy on the Clinical Study of ？Chinese Lung Cancer Immunotherapy

Starting from the success of anti-CTLA-4 antibody in malignant melanoma, targeted immunotherapy has become one of the effective strategies for anti-tumor therapy, and raised a new wave of research on tumor immunotherapy. In the field of lung cancer, a series of clinical studies on immune-targeted drugs have been carried out aboard, nivolumab, pembrolizumab and atezolizumab have been approved for the treatment of lung cancer, which rewrite the history of lung cancer treatment. In China, clinical studies on immune-targeted drugs for lung cancer have also been developed. The present study mainly analyzed and investigated the current situation, gap and future innovation of the research on anti-tumor immunity of lung cancer in China.